Richard S Clayton

Title: Richard S Clayton: Innovator in Human Secretoglobin Proteins

Introduction

Richard S Clayton is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of biotechnology, particularly in the modification and composition of human secretoglobin proteins. With a total of 4 patents, his work has the potential to impact various medical conditions.

Latest Patents

One of Clayton's latest patents focuses on the modification and compositions of recombinant human CC10 protein. This innovative work involves chemically modifying the pure protein in vitro to create several new synthetic preparations containing isoforms of chemically modified rhCC10. These preparations utilize reactive oxygen species and reactive nitrogen species, resulting in novel isoforms of rhCC10 that exhibit enhanced or altered biological properties compared to the unmodified protein. The new isoforms may serve as standards for identifying and characterizing naturally occurring isoforms of native CC10 protein from blood or urine. Ultimately, this research aims to measure new CC10-based biomarkers to assess patient disease status. Additionally, these preparations may be utilized to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively addressed by the unmodified protein.

Career Highlights

Throughout his career, Richard S Clayton has worked with several prominent companies, including Therabron Therapeutics, Inc. and Apc Research Assets, LLC. His expertise in biotechnology and protein modification has positioned him as a key figure in his field.

Collaborations

Clayton has collaborated with notable colleagues such as Humcha K Hariprakasha and Melissa E Winn, contributing to the advancement of research in human secretoglobin proteins.

Conclusion

Richard S Clayton's innovative work in the field of human secretoglobin proteins showcases his dedication to advancing medical science. His patents and collaborations highlight the potential for new treatments and biomarkers that could significantly improve patient care.